Concord Biotech Limited
3,884words
1turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
Symbol: CONCORDBIO To General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960 Dear Sir/Ma’am, Sub.: Investor’s Presentatio
70.1%
FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25
73.7%
Y26 Q4FY25 Q4FY26 FY25 FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25 FY26
74.5%
FY25 Q4FY26 FY25 FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25 FY26 Q4FY25
76.7%
4FY26 FY25 FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26
44.3%
FY25 FY26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25
36.4%
Y26 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26
42.2%
oss Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Q4FY25
34.8%
fit Margin (%) EBIDTA Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26
32.7%
gin (%) EBIDTA Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25
27.1%
EBIDTA Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26
31.0%
A Margin (%) PAT Margin (%) 70.1% 73.7% 74.5% 76.7% 44.3% 36.4% 42.2% 34.8% 32.7% 27.1% 31.0% 24.6% Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 EBIDTA
Speaking time
Investor Relations Advisor
1
Opening remarks
Investor Relations Advisor
Concord Biotech Limited CIN: L24230GJ1984PLC007440 Mr. Raviraj Karia – Chief Financial Officer ravirajkaria@concordbiotech.com www.concordbiotech.com Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Sagar Shroff / Mr. Vatsal Shah sagar.shroff@sgapl.net / vatsal.shah@sgapl.net +91 98205 19303 / +91 88796 59884 www.sgapl.net